Dr. Reddy's Laboratories (DRREDDY) — Board Meeting

Dr. Reddy's Laboratories reported Q3 FY26 consolidated revenues of ₹87,268 million, up 4.4% YoY but flat sequentially. Nine-month revenues reached ₹260,771 million with 8.4% YoY growth. However, gross margins compressed significantly to 53.6% from 58.7% YoY, driven by lower Lenalidomide sales and price erosion. Q3 net profit declined 14% YoY to ₹12.1 billion. One-time charges included ₹535 million impairment on discontinued conjugated estrogen and ₹695 million VAT provision. The company faces ongoing DOJ/SEC investigations regarding alleged improper payments in Ukraine and other markets.

📄 View Original Announcement (PDF)

📊 Stock Analysis — DRREDDY ✨ Ask AI About This

About Dr. Reddy's Laboratories Limited (DRREDDY)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,11,568.6 Cr P/E: 20.0 ROE: 16.6% ROCE: 19.7%

View full DRREDDY stock details →

📡 Get AI alerts when DRREDDY files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DRREDDY — Free

💡 Ask AI about this filing

"How does this board meeting affect Dr. Reddy's Laboratories Limited's outlook?" "What did Dr. Reddy's Laboratories Limited announce on 21 January 2026?" "Is this positive or negative for DRREDDY?"

Ask AI Free →

📊 More DRREDDY filings

See all DRREDDY filings →

🔥 Also filed on 21 January 2026

SRF SRF Limited Corporate Action SRF SRF Limited Financial Results TATASTEEL Tata Steel Limited Announcement VEDL Vedanta Limited Corporate Action SUNPHARMA Sun Pharmaceutical Industries Limited Financial Results BEL Bharat Electronics Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DRREDDY files new disclosures

Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.